-
Epignostix launches advanced DNA methylation-based sarcoma classifier
Heidelberg, Germany, July 8, 2025 – Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces the successful launch of a substantial update to their sarcoma tumour classifier- marking a substantial milestone in establishing precision tumour classification beyond tumours of the central nervous system. Combining epigenetics with artificial intelligence-powered bioinformatics, their software algorithms […]
-
Epignostix announces CMS release of a preliminary gapfill price for their proprietary CPT Code for the Epignostix CNS Tumor Methylation Classifier test
Heidelberg, Germany, May 6, 2025 Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics, announces today that the Centers for Medicare & Medicaid Services (CMS) have released a preliminary Medicare reimbursement rate for the CPT® (Current Procedural Technology) code for the Company’s proprietary Epignostix CNS Tumor Methylation Classifier – a molecular test for precision diagnostics of […]
-
Epignostix launches CNS and sarcoma diagnostic tumor classifier applications
Heidelberg, Germany, January 22, 2025 Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces the successful launch of their CNS and sarcoma tumor classifiers- marking a substantial milestone in driving market development for their flagship indication, CNS tumor classification, and expansion to additional applications. Combining epigenetics […]
